Farid Vij is Vice President of Corporate Development at Ciitizen where he drives the company’s go-to-market strategy and engagements with partners including patient advocacy organizations, providers and biotech/biopharma. Farid’s focus is on creating a scalable model that allows advocacy partners and patients to garner value through sharing their health data yet retaining control of it at all times. He believes there is a sustainable way to drive patient-driven research by ensuring patients always gain benefit through their participation. Prior to Ciitizen, Farid was Global Head of Sales & Business Development at ZL Technologies where he led the development and launch of ZL’s Big Data cloud business to support legal compliance with GDPR and built a global sales and marketing organization across four regions. Farid received a B.S. in Economics from the Wharton School at the University of Pennsylvania.
Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.